Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
|
2.9B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Bafna Pharmaceuticals Ltd
Glance View
Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is manufacturing over 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. The firm caters to both domestic and international markets. The firm has two manufacturing facilities in Chennai. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The firm supplies its finished products to countries including Sri Lanka, Ghana, Ukraine, and Laos. The firm's subsidary include Bafna Lifestyles Remedies Limited.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Bafna Pharmaceuticals Ltd is 6.2%, which is above its 3-year median of 5.7%.
Over the last 3 years, Bafna Pharmaceuticals Ltd’s Net Margin has increased from 4.9% to 6.2%. During this period, it reached a low of 0.2% on Jun 30, 2024 and a high of 11.6% on Jun 30, 2023.
